DE60127846T2 - Tricyclic antitumor komponenten als farnesyl protein transferase inhibitoren - Google Patents
Tricyclic antitumor komponenten als farnesyl protein transferase inhibitoren Download PDFInfo
- Publication number
- DE60127846T2 DE60127846T2 DE60127846T DE60127846T DE60127846T2 DE 60127846 T2 DE60127846 T2 DE 60127846T2 DE 60127846 T DE60127846 T DE 60127846T DE 60127846 T DE60127846 T DE 60127846T DE 60127846 T2 DE60127846 T2 DE 60127846T2
- Authority
- DE
- Germany
- Prior art keywords
- substituted
- compound
- alkyl
- mmol
- give
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(*)Nc1cnc[n]1 Chemical compound CC(*)Nc1cnc[n]1 0.000 description 43
- FLHXHSKTABNPDY-UHFFFAOYSA-N CN(CC1)CCC1C1c2ccccc2C(Br)=Cc2ccccc12 Chemical compound CN(CC1)CCC1C1c2ccccc2C(Br)=Cc2ccccc12 FLHXHSKTABNPDY-UHFFFAOYSA-N 0.000 description 2
- FZVBHRRTRHNMJY-UHFFFAOYSA-N Cc1c(C)nc[n]1CCCC(c1c(C2C3CCNCC3)ccc(Cl)c1)=Cc1c2nccc1 Chemical compound Cc1c(C)nc[n]1CCCC(c1c(C2C3CCNCC3)ccc(Cl)c1)=Cc1c2nccc1 FZVBHRRTRHNMJY-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N C1CCNCC1 Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- HYTQIJWXBOJSLE-IGTJQSIKSA-O CC#C/C=C\C=[NH+]\OC Chemical compound CC#C/C=C\C=[NH+]\OC HYTQIJWXBOJSLE-IGTJQSIKSA-O 0.000 description 1
- LMGQEJPTROIWAP-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(c(ccc(Cl)c1)c1C(CCCC1C=NC(C)=CC1)=C1)C2=C1C#CC=C=C2)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(c(ccc(Cl)c1)c1C(CCCC1C=NC(C)=CC1)=C1)C2=C1C#CC=C=C2)=O LMGQEJPTROIWAP-UHFFFAOYSA-N 0.000 description 1
- ABFHRRJGVMYFFM-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C1c2ccccc2C(C=C)=Cc2ccccc12)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C1c2ccccc2C(C=C)=Cc2ccccc12)=O ABFHRRJGVMYFFM-UHFFFAOYSA-N 0.000 description 1
- WRUSGHNLOFJSCT-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C1c2ncccc2C(CCC[n]2cncc2)=Cc2cc(Cl)ccc12)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C1c2ncccc2C(CCC[n]2cncc2)=Cc2cc(Cl)ccc12)=O WRUSGHNLOFJSCT-UHFFFAOYSA-N 0.000 description 1
- BSHCLIGDTSJICO-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C1c2ncccc2C=C(C(O)=O)c2cc(Cl)ccc12)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C1c2ncccc2C=C(C(O)=O)c2cc(Cl)ccc12)=O BSHCLIGDTSJICO-UHFFFAOYSA-N 0.000 description 1
- CWKFIFUBSRMNFP-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C1c2ncccc2C=C(CCC[n]2cnc(C)c2)c2cc(Cl)ccc12)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C1c2ncccc2C=C(CCC[n]2cnc(C)c2)c2cc(Cl)ccc12)=O CWKFIFUBSRMNFP-UHFFFAOYSA-N 0.000 description 1
- AGCPTPYYYCOTOZ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C1c2ncccc2C=C(COS(C)(=O)=O)c2cc(Cl)ccc12)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C1c2ncccc2C=C(COS(C)(=O)=O)c2cc(Cl)ccc12)=O AGCPTPYYYCOTOZ-UHFFFAOYSA-N 0.000 description 1
- GISKBRJTOXVUTD-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C(c1ccccc1C(C(O)=O)=Cc1c2)c1ncc2Br)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C(c1ccccc1C(C(O)=O)=Cc1c2)c1ncc2Br)=O GISKBRJTOXVUTD-UHFFFAOYSA-N 0.000 description 1
- ZRXGTMAFNONIFJ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C(c1ccccc1C=C(C(O)=O)c1c2)c1ncc2Br)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C(c1ccccc1C=C(C(O)=O)c1c2)c1ncc2Br)=O ZRXGTMAFNONIFJ-UHFFFAOYSA-N 0.000 description 1
- GICHVHNIQFUZRI-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C(c1ccccc1C=C(CO)c1c2)c1ncc2Br)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C(c1ccccc1C=C(CO)c1c2)c1ncc2Br)=O GICHVHNIQFUZRI-UHFFFAOYSA-N 0.000 description 1
- GDPDJFBLENQQRP-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C1c(nccc2)c2C=C(Cc2cnc[n]2C)c2c1ccc(Cl)c2)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C1c(nccc2)c2C=C(Cc2cnc[n]2C)c2c1ccc(Cl)c2)=O GDPDJFBLENQQRP-UHFFFAOYSA-N 0.000 description 1
- MNWWNXWZHQEYKR-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C1c2ncccc2C=C(CBr)c2cc(Cl)ccc12)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C1c2ncccc2C=C(CBr)c2cc(Cl)ccc12)=O MNWWNXWZHQEYKR-UHFFFAOYSA-N 0.000 description 1
- FHDGXULNXYKVCQ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C1c2ncccc2C=C(COS(C)(=O)=O)c2cc(Cl)ccc12)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C1c2ncccc2C=C(COS(C)(=O)=O)c2cc(Cl)ccc12)=O FHDGXULNXYKVCQ-UHFFFAOYSA-N 0.000 description 1
- OJCLHERKFHHUTB-VIFPVBQESA-N CC(C)(C)OC(N1C[C@@H](CO)CCC1)=O Chemical compound CC(C)(C)OC(N1C[C@@H](CO)CCC1)=O OJCLHERKFHHUTB-VIFPVBQESA-N 0.000 description 1
- DMGPVORHOIVYLQ-UHFFFAOYSA-N CC(C)NC(CCCCl)=O Chemical compound CC(C)NC(CCCCl)=O DMGPVORHOIVYLQ-UHFFFAOYSA-N 0.000 description 1
- WLSJWLBGYYDHKE-UHFFFAOYSA-N CCC(C(c1ccccc1)N(CC1)CCN1C(OC(C)(C)C)=O)=N Chemical compound CCC(C(c1ccccc1)N(CC1)CCN1C(OC(C)(C)C)=O)=N WLSJWLBGYYDHKE-UHFFFAOYSA-N 0.000 description 1
- JEQNHRNCYDIAEY-UHFFFAOYSA-N CCC(C)(CC(C)(C)C)[n]1cncc1 Chemical compound CCC(C)(CC(C)(C)C)[n]1cncc1 JEQNHRNCYDIAEY-UHFFFAOYSA-N 0.000 description 1
- PZVFQOBASICMME-UHFFFAOYSA-N CCNS(C)(=O)=O Chemical compound CCNS(C)(=O)=O PZVFQOBASICMME-UHFFFAOYSA-N 0.000 description 1
- SIPSCQWLZZEZOA-UHFFFAOYSA-N CCOC(C(c1cc(Br)cnc1C1C2CCNCC2)=Cc2c1ccc(Cl)c2)=O Chemical compound CCOC(C(c1cc(Br)cnc1C1C2CCNCC2)=Cc2c1ccc(Cl)c2)=O SIPSCQWLZZEZOA-UHFFFAOYSA-N 0.000 description 1
- IHSUFLCKRIHFGY-UHFFFAOYSA-N CCOC(CC1CCNCC1)=O Chemical compound CCOC(CC1CCNCC1)=O IHSUFLCKRIHFGY-UHFFFAOYSA-N 0.000 description 1
- NJQHZENQKNIRSY-UHFFFAOYSA-N CCc1c[nH]cn1 Chemical compound CCc1c[nH]cn1 NJQHZENQKNIRSY-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N CN1CCNCC1 Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- UZPUVQBDELWKOP-UHFFFAOYSA-N COC(C(c1c2)=Cc3cccnc3C(C3CCNCC3)c1ccc2Cl)=O Chemical compound COC(C(c1c2)=Cc3cccnc3C(C3CCNCC3)c1ccc2Cl)=O UZPUVQBDELWKOP-UHFFFAOYSA-N 0.000 description 1
- APUJVOCZJKISSC-UHFFFAOYSA-N CS(N(CC1)CCC1C1c2ncccc2C(CCCN(CCC2)C2=O)=Cc2cc(Cl)ccc12)(=O)=O Chemical compound CS(N(CC1)CCC1C1c2ncccc2C(CCCN(CCC2)C2=O)=Cc2cc(Cl)ccc12)(=O)=O APUJVOCZJKISSC-UHFFFAOYSA-N 0.000 description 1
- YYFUPDPDJCPQAN-UHFFFAOYSA-N CS(N(CC1)CCC1C1c2ncccc2C(CI)=Cc2cc(Cl)ccc12)(=O)=O Chemical compound CS(N(CC1)CCC1C1c2ncccc2C(CI)=Cc2cc(Cl)ccc12)(=O)=O YYFUPDPDJCPQAN-UHFFFAOYSA-N 0.000 description 1
- MISIFKLJDQPYTI-UHFFFAOYSA-N Cc(c(C=C)c1)ccc1Cl Chemical compound Cc(c(C=C)c1)ccc1Cl MISIFKLJDQPYTI-UHFFFAOYSA-N 0.000 description 1
- FXDRWCPBGYJWRL-ONEGZZNKSA-N Cc1ncc[n]1C/C=C/C1=Cc2cc(Cl)ccc2C(C2CCNCC2)c2ncccc12 Chemical compound Cc1ncc[n]1C/C=C/C1=Cc2cc(Cl)ccc2C(C2CCNCC2)c2ncccc12 FXDRWCPBGYJWRL-ONEGZZNKSA-N 0.000 description 1
- YWMQUUJHWXWOKF-UHFFFAOYSA-N Cc1ncc[n]1CC(C1=C2NCC(Br)=C1)=Cc1ccccc1C2N(CC1)CCN1C(Nc(cc1)ccc1C#N)=O Chemical compound Cc1ncc[n]1CC(C1=C2NCC(Br)=C1)=Cc1ccccc1C2N(CC1)CCN1C(Nc(cc1)ccc1C#N)=O YWMQUUJHWXWOKF-UHFFFAOYSA-N 0.000 description 1
- QBZDCOANGJIRPP-UHFFFAOYSA-N Cc1ncc[n]1CC(c1cc(Br)cnc11)=Cc2cc(Cl)ccc2C1N(CC1)CCN1C(Nc(cc1)ccc1O)=O Chemical compound Cc1ncc[n]1CC(c1cc(Br)cnc11)=Cc2cc(Cl)ccc2C1N(CC1)CCN1C(Nc(cc1)ccc1O)=O QBZDCOANGJIRPP-UHFFFAOYSA-N 0.000 description 1
- DXBSRBPBKURCAB-UHFFFAOYSA-N Cc1ncc[n]1CC(c1cc(Cl)cnc11)=Cc2ccccc2C1N(CC1)CCN1C(Nc(cc1)ccc1C#N)=O Chemical compound Cc1ncc[n]1CC(c1cc(Cl)cnc11)=Cc2ccccc2C1N(CC1)CCN1C(Nc(cc1)ccc1C#N)=O DXBSRBPBKURCAB-UHFFFAOYSA-N 0.000 description 1
- GOPDSGRNPORGCE-UHFFFAOYSA-N Cc1ncc[n]1CC1=Cc2ccccc2C(C2CCNCC2)c2ccccc12 Chemical compound Cc1ncc[n]1CC1=Cc2ccccc2C(C2CCNCC2)c2ccccc12 GOPDSGRNPORGCE-UHFFFAOYSA-N 0.000 description 1
- AUELWJRRASQDKI-UHFFFAOYSA-N NC(OC1CCCCC1)=O Chemical compound NC(OC1CCCCC1)=O AUELWJRRASQDKI-UHFFFAOYSA-N 0.000 description 1
- BSKDLJZSLLXZOE-UHFFFAOYSA-N O=C(Cc1ccncc1)OCCl Chemical compound O=C(Cc1ccncc1)OCCl BSKDLJZSLLXZOE-UHFFFAOYSA-N 0.000 description 1
- YMHMOEJBUFBBCZ-UHFFFAOYSA-N O=C1c2ncccc2C(Br)=Cc2cc(Cl)ccc12 Chemical compound O=C1c2ncccc2C(Br)=Cc2cc(Cl)ccc12 YMHMOEJBUFBBCZ-UHFFFAOYSA-N 0.000 description 1
- ZQEXIXXJFSQPNA-UHFFFAOYSA-N O=Cc1c[nH]cn1 Chemical compound O=Cc1c[nH]cn1 ZQEXIXXJFSQPNA-UHFFFAOYSA-N 0.000 description 1
- ZGWLIGZALJYZHU-UHFFFAOYSA-N OC1c2ccccc2C(Br)=Cc2ccccc12 Chemical compound OC1c2ccccc2C(Br)=Cc2ccccc12 ZGWLIGZALJYZHU-UHFFFAOYSA-N 0.000 description 1
- ISFHVRIHILJZLI-UHFFFAOYSA-N OCC(c1cc(Br)cnc1C1C2CCNCC2)=Cc2c1ccc(Cl)c2 Chemical compound OCC(c1cc(Br)cnc1C1C2CCNCC2)=Cc2c1ccc(Cl)c2 ISFHVRIHILJZLI-UHFFFAOYSA-N 0.000 description 1
- VUNPWIPIOOMCPT-UHFFFAOYSA-N OCC1CNCCC1 Chemical compound OCC1CNCCC1 VUNPWIPIOOMCPT-UHFFFAOYSA-N 0.000 description 1
- VUNPWIPIOOMCPT-LURJTMIESA-N OC[C@@H]1CNCCC1 Chemical compound OC[C@@H]1CNCCC1 VUNPWIPIOOMCPT-LURJTMIESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22918300P | 2000-08-30 | 2000-08-30 | |
| US229183P | 2000-08-30 | ||
| PCT/US2001/026792 WO2002018368A1 (en) | 2000-08-30 | 2001-08-28 | Tricyclic antitumor compounds being farnesyl protein transferase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60127846D1 DE60127846D1 (en) | 2007-05-24 |
| DE60127846T2 true DE60127846T2 (de) | 2008-03-06 |
Family
ID=22860141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60127846T Expired - Fee Related DE60127846T2 (de) | 2000-08-30 | 2001-08-28 | Tricyclic antitumor komponenten als farnesyl protein transferase inhibitoren |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20020198216A1 (enExample) |
| EP (1) | EP1313725B1 (enExample) |
| JP (1) | JP2004513885A (enExample) |
| KR (1) | KR20030034161A (enExample) |
| CN (1) | CN100384837C (enExample) |
| AR (1) | AR033680A1 (enExample) |
| AT (1) | ATE359281T1 (enExample) |
| AU (2) | AU8845101A (enExample) |
| BR (1) | BR0113675A (enExample) |
| CA (1) | CA2420673A1 (enExample) |
| CO (1) | CO5640109A2 (enExample) |
| DE (1) | DE60127846T2 (enExample) |
| EC (1) | ECSP034494A (enExample) |
| ES (1) | ES2284686T3 (enExample) |
| HK (1) | HK1054548B (enExample) |
| HU (1) | HUP0302942A3 (enExample) |
| IL (1) | IL154528A0 (enExample) |
| MX (1) | MXPA03001849A (enExample) |
| NO (1) | NO20030918L (enExample) |
| NZ (1) | NZ524246A (enExample) |
| PE (1) | PE20020486A1 (enExample) |
| PL (1) | PL361103A1 (enExample) |
| RU (1) | RU2293734C9 (enExample) |
| SK (1) | SK2292003A3 (enExample) |
| TW (1) | TWI268280B (enExample) |
| WO (1) | WO2002018368A1 (enExample) |
| ZA (1) | ZA200301545B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7342016B2 (en) | 2000-08-30 | 2008-03-11 | Schering Corporation | Farnesyl protein transferase inhibitors as antitumor agents |
| EE05417B1 (et) * | 2001-03-14 | 2011-06-15 | Bristol-Myers Squibb Company | Epotilooni analoogide ja kemoterapeutikumide kombinatsiooni kasutamine teraapias |
| JP2005531488A (ja) * | 2001-10-09 | 2005-10-20 | ザ・ユニバーシティ・オブ・シンシナティ | 甲状腺癌を処置するためのｅｇｆ受容体阻害剤 |
| EP1448268A2 (en) * | 2001-11-30 | 2004-08-25 | Schering Corporation | Use of an farnesyl protein transferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer |
| JP2005515201A (ja) * | 2001-12-03 | 2005-05-26 | シェーリング コーポレイション | 癌の処置におけるｆｐｔインヒビターおよび少なくとも２つの抗腫瘍性剤の使用 |
| US20030195192A1 (en) * | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| US20040014744A1 (en) * | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| EP1606285A4 (en) * | 2003-03-27 | 2009-03-18 | Lankenau Inst Medical Res | NEW IDO HEMMER AND APPLICATION PROCEDURES |
| EP1628631A2 (en) * | 2003-06-05 | 2006-03-01 | Achkar, Charles C. | Methods of treating hyperproliferative cell disorders |
| BRPI0411250A (pt) * | 2003-06-09 | 2006-08-29 | Samuel Waksal | método de inibição de receptor tirosina cinase com um antagonista extracelular e um antagonista intracellular |
| ES2235611B2 (es) * | 2003-07-25 | 2006-07-16 | Universidade De Santiago De Compostela | Metodo cuantitativo para la deteccion de yesotoxinas en productos pesqueros basado en la activacion que producen en las fosfodiesterasas. |
| BRPI0413384A (pt) * | 2003-08-07 | 2006-10-17 | Schering Corp | inibidores da proteìna farnesil transferase como agentes antitumores |
| US7592466B2 (en) | 2003-10-09 | 2009-09-22 | Abbott Laboratories | Ureas having antiangiogenic activity |
| MY138124A (en) * | 2004-12-21 | 2009-04-30 | Schering Corp | Novel farnesyl protein transferase inhibitors as antitumor agents |
| RU2361587C1 (ru) * | 2008-02-14 | 2009-07-20 | Михаил Владимирович Кутушов | Лекарственное средство для лечения онкологических заболеваний |
| CA2730190A1 (en) * | 2008-07-14 | 2010-01-21 | Queen's University At Kingston | Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer |
| WO2020258211A1 (en) * | 2019-06-28 | 2020-12-30 | Anhui Ronghang Biotech Development Co., Ltd. | Compositions and methods for treatment of hepatitis b virus infection |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5089496A (en) * | 1986-10-31 | 1992-02-18 | Schering Corporation | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies |
| IL98572A (en) * | 1990-06-22 | 1995-07-31 | Schering Corp | Bis-benzo or benzopyrido cyclohepta piperidene, piperidylidene and piperazine compositions an methods of use |
| US5719148A (en) * | 1993-10-15 | 1998-02-17 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| PE92098A1 (es) * | 1996-07-31 | 1998-12-31 | Schering Corp | N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo |
| US6071907A (en) * | 1996-09-13 | 2000-06-06 | Schering Corporation | Tricyclic compounds useful as FPT inhibitors |
| US5925648A (en) * | 1997-07-29 | 1999-07-20 | Schering Corporation | Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase |
| CA2354774C (en) * | 1998-12-18 | 2009-05-26 | Schering Corporation | Farnesyl protein transferase inhibitors |
-
2001
- 2001-08-27 AR ARP010104082A patent/AR033680A1/es unknown
- 2001-08-28 HU HU0302942A patent/HUP0302942A3/hu unknown
- 2001-08-28 IL IL15452801A patent/IL154528A0/xx unknown
- 2001-08-28 CN CNB01818121XA patent/CN100384837C/zh not_active Expired - Fee Related
- 2001-08-28 TW TW090121201A patent/TWI268280B/zh active
- 2001-08-28 WO PCT/US2001/026792 patent/WO2002018368A1/en not_active Ceased
- 2001-08-28 PE PE2001000865A patent/PE20020486A1/es not_active Application Discontinuation
- 2001-08-28 MX MXPA03001849A patent/MXPA03001849A/es active IP Right Grant
- 2001-08-28 KR KR10-2003-7003012A patent/KR20030034161A/ko not_active Ceased
- 2001-08-28 AU AU8845101A patent/AU8845101A/xx active Pending
- 2001-08-28 AU AU2001288451A patent/AU2001288451C1/en not_active Ceased
- 2001-08-28 BR BR0113675-5A patent/BR0113675A/pt not_active IP Right Cessation
- 2001-08-28 SK SK229-2003A patent/SK2292003A3/sk not_active Application Discontinuation
- 2001-08-28 NZ NZ524246A patent/NZ524246A/en unknown
- 2001-08-28 PL PL01361103A patent/PL361103A1/xx unknown
- 2001-08-28 AT AT01968188T patent/ATE359281T1/de not_active IP Right Cessation
- 2001-08-28 RU RU2003108865/04A patent/RU2293734C9/ru not_active IP Right Cessation
- 2001-08-28 HK HK03105016.6A patent/HK1054548B/en not_active IP Right Cessation
- 2001-08-28 EP EP01968188A patent/EP1313725B1/en not_active Expired - Lifetime
- 2001-08-28 JP JP2002523486A patent/JP2004513885A/ja active Pending
- 2001-08-28 DE DE60127846T patent/DE60127846T2/de not_active Expired - Fee Related
- 2001-08-28 US US09/940,811 patent/US20020198216A1/en not_active Abandoned
- 2001-08-28 ES ES01968188T patent/ES2284686T3/es not_active Expired - Lifetime
- 2001-08-28 CA CA002420673A patent/CA2420673A1/en not_active Abandoned
-
2003
- 2003-02-25 ZA ZA200301549A patent/ZA200301545B/xx unknown
- 2003-02-26 EC EC2003004494A patent/ECSP034494A/es unknown
- 2003-02-27 CO CO03017118A patent/CO5640109A2/es active IP Right Grant
- 2003-02-27 NO NO20030918A patent/NO20030918L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60127846T2 (de) | Tricyclic antitumor komponenten als farnesyl protein transferase inhibitoren | |
| DE69628556T2 (de) | Tricyclische verbindungen als inhibitoren von farnesyl protein transferase | |
| DE69628559T2 (de) | Carbonyl-piperaznyl und piperidinyl derivate zur hemmung farnesyl protein transferase | |
| DE60217363T2 (de) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen-abhängigen erkrankungen | |
| DE69622265T2 (de) | Trizyklische verbindungen zur behandlung von zellproliferativen störungen | |
| DE69637105T2 (de) | Tricyclische derivate anwendbar als g-protein inhibitoren und für die behandlung von proliferative erkrankungen | |
| DE69627993T2 (de) | Trycyclische derivate zur inhibierung der g-protein funktion und für die behandlung von proliferativen erkrankungen | |
| DE69831937T2 (de) | Bicyclische protein-farnesyl-transferase inhibitoren | |
| DE69732120T2 (de) | Trizyklische inhibitoren der farnesyl protein transferase | |
| DE60020560T2 (de) | Substituierte pyrazol-derivate | |
| DE69924876T2 (de) | Farnesyl protein transferase inhibitoren | |
| DE60038498T2 (de) | Triazole als Farnesyltransferaseinhibitoren | |
| DE69705324T2 (de) | N-hydroxyharnstoffderivate und sie enthaltende medizinische zubereitungen | |
| JP2005515201A (ja) | 癌の処置におけるｆｐｔインヒビターおよび少なくとも２つの抗腫瘍性剤の使用 | |
| US20030229099A1 (en) | Novel farnesyl protein transferase inhibitors as antitumor agents | |
| DE69626321T2 (de) | Substituierte 4-(1h-benzimidazol-2-yl-amino)piperidine zur behandlung allergischer erkrankungen | |
| US7342016B2 (en) | Farnesyl protein transferase inhibitors as antitumor agents | |
| DE69825589T2 (de) | Benzpyrido cycloheptan derivate mit farnesyl protein transferase inhibierender wirkung | |
| AU2001288451A1 (en) | Tricyclic antitumor compounds being farnesyl protein transferase inhibitors | |
| DE69736950T2 (de) | Tricyclische piperdinyl derivate verwendbar als farnesyl-protein transferase inhibitoren | |
| DE69732123T2 (de) | Trizyklische Verindung mit Farnesylproteintransferase inhibierender Wirkung | |
| DE69825608T2 (de) | Benzo[5,6]cycloheptapyridin derivate anwendbar als farnesyl protein transferase inhibitoren | |
| DE69926078T2 (de) | Farnesyl-protein transferase inhibitoren | |
| DE69634183T2 (de) | Substituierte Heterocyclen | |
| DE69717969T2 (de) | Substituierte n-methyl-n-(4-(piperidin-1-yl)-2-arylbutyl)-benzamide zur behandlung von allergischen erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: SCHERING CORP., KENILWORTH, N.J., US Owner name: PHARMACOPEIA, INC., CRANBURY, N.J., US |
|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |